RESUMEN
Dystonia is a movement disorder of both genetic and non-genetic causes, which typically results in twisted posturing due to abnormal muscle contraction. Evidence from dystonia patients and animal models of dystonia indicate a crucial role for the striatal cholinergic system in the pathophysiology of dystonia. In this review, we focus on striatal circuitry and the centrality of the acetylcholine system in the function of the basal ganglia in the control of voluntary movement and ultimately clinical manifestation of movement disorders. We consider the impact of cholinergic interneurons (ChIs) on dopamine-acetylcholine interactions and examine new evidence for impairment of ChIs in dysfunction of the motor systems producing dystonic movements, particularly in animal models. We have observed paradoxical excitation of ChIs in the presence of dopamine D2 receptor agonists and impairment of striatal synaptic plasticity in a mouse model of DYT1 dystonia, which are improved by administration of recently developed M1 receptor antagonists. These findings have been confirmed across multiple animal models of DYT1 dystonia and may represent a common endophenotype by which to investigate dystonia induced by other types of genetic and non-genetic causes and to investigate the potential effectiveness of pharmacotherapeutics and other strategies to improve dystonia.
Asunto(s)
Acetilcolina/metabolismo , Cuerpo Estriado/fisiopatología , Trastornos Distónicos/fisiopatología , Interneuronas/fisiología , Animales , Cuerpo Estriado/anatomía & histología , HumanosRESUMEN
Lesions of nigrostriatal dopaminergic neurons as seen in Parkinson's disease (PD) increase orofacial responses to serotonergic (5-HT) agonists in rodents. Although this response to 5-HT agonists has been related to aberrant signalling in the basal ganglia, a group a subcortical structures involved in the control of motor behaviours, it deserves additional studies with respect to the specific loci involved. Using measurements of orofacial activity, as well as single-cell recordings in vivo, we have studied the role of the entopeduncular nucleus (EPN; equivalent to the internal globus pallidus of primates), an output structure of basal ganglia, in the hypersensitized responses to a 5-HT agonist in sham- or unilaterally dopamine-depleted rats. Intra-EPN injections of Ro 60-0175 (0.3 and 1 µg/100 nl) promoted robust oral movements in 6-OHDA rats without affecting oral activity in sham-depleted rats. Peripheral administration of Ro 60-0175 (3 mg/kg ip) decreased EPN neuronal firing rate in 6-OHDA rats compared to sham-depleted rats. Such an effect was also observed when the agonist (0.2 µg/20 nl) was locally applied onto EPN neurons. These data demonstrate the contribution of EPN to hypersensitized responses to 5-HT agonists in a rat model of PD.
Asunto(s)
Núcleo Entopeduncular/efectos de los fármacos , Etilaminas/farmacología , Indoles/farmacología , Neuronas/efectos de los fármacos , Enfermedad de Parkinson/tratamiento farmacológico , Agonistas del Receptor de Serotonina 5-HT2/farmacología , Administración Oral , Animales , Ganglios Basales/efectos de los fármacos , Ganglios Basales/metabolismo , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/metabolismo , Modelos Animales de Enfermedad , Fenómenos Electrofisiológicos/fisiología , Núcleo Entopeduncular/metabolismo , Etilaminas/administración & dosificación , Globo Pálido/efectos de los fármacos , Globo Pálido/metabolismo , Indoles/administración & dosificación , Masculino , Enfermedad de Parkinson/metabolismo , Ratas , Ratas Sprague-Dawley , Serotonina/metabolismo , Agonistas del Receptor de Serotonina 5-HT2/administración & dosificación , Sustancia Negra/efectos de los fármacos , Sustancia Negra/metabolismoRESUMEN
Exposure to the pesticide paraquat (PQ) increases the risk of Parkinson's disease (PD), and its effect may be modulated by genetic or other environmental factors. The neuropeptide PACAP (pituitary adenylyl cyclase-activating polypeptide, Adcyap1) has been shown to enhance tyrosine hydroxylase (TH) and VMAT2 expression, protect dopaminergic (DA) neurons against the neurotoxin 6-hydroxydopamine, regulate neuronal mitochondria, and inhibit inflammation. Decreased expression of PACAP may thus interact with environmental factors such as PQ to increase the risk of PD. To mimic a low level environmental exposure to PQ, wild type (WT) and PACAP knockout (KO) mice were given a single [10 mg/kg] dose of PQ, a regimen that did not induce the loss of TH expression or DA neurons in WT mice. This treatment selectively reduced the number of TH-positive cell bodies in the substantia nigra pars compacta (SNpc) selectively in PACAP KO mice. Because inflammation is also a risk factor for PD, we performed a quantitative analysis of SNpc Iba⺠microglia. As expected, PQ increased the number of larger microglial profiles, indicative of activation, in WT mice. Strikingly, microglial activation was already evident in PACAP KO mice in the basal state. PQ caused no further activation in these mice, although tumor necrosis factor-α gene expression was enhanced. In the periphery, PQ had no effects on the abundance of proinflammatory Th1 or Th17 cells in WT mice, but increased the numbers of anti-inflammatory regulatory T cells (Tregs). PACAP KO mice, in contrast, had elevated numbers of Th17 cells after PQ, and the induction of Tregs was impaired. The results indicate that endogenous PACAP acts to maintain the integrity of DA neurons during exposure to PQ, an action that may be linked to its ability to regulate microglia and/or other immune cells.
Asunto(s)
Neuronas Dopaminérgicas/patología , Síndromes de Neurotoxicidad/inmunología , Síndromes de Neurotoxicidad/patología , Polipéptido Hipofisario Activador de la Adenilato-Ciclasa/deficiencia , Sustancia Negra/patología , Linfocitos T/patología , Análisis de Varianza , Animales , Proteínas de Unión al Calcio/metabolismo , Proteínas de Unión al ADN , Modelos Animales de Enfermedad , Neuronas Dopaminérgicas/metabolismo , Herbicidas/toxicidad , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Proteínas de Microfilamentos/metabolismo , Microglía/patología , Síndromes de Neurotoxicidad/etiología , Paraquat/toxicidad , Sustancia Negra/efectos de los fármacos , Linfocitos T/efectos de los fármacos , Linfocitos T/metabolismo , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/metabolismo , Tirosina 3-Monooxigenasa/metabolismoRESUMEN
BACKGROUND: Prevalent non-motor symptoms of Parkinson's disease (PD) include gastrointestinal motor impairments and advanced stage PD displays pathological aggregates of α-synuclein in colonic enteric neurons. We previously showed that 12 months old mice overexpressing human wild type (WT) α-synuclein under the Thy1 promoter (Thy1-aSyn) displayed colonic motor dysfunction. We investigated functional gut alterations at earlier ages and histological correlates. METHODS: Defecation, gastric emptying (GE), and immunostaining for α-synuclein, peripheral choline acetyltransferase (pChAT), tyrosine hydroxylase (TH), neuronal nitric oxide synthase (nNOS), and vasoactive intestinal peptide (VIP) in distal colon myenteric plexuses were assessed in male Thy1-aSyn compared to littermate WT mice. KEY RESULTS: Thy1-aSyn mice aged 2.5-3 or 7-8 months old had 81% and 55% reduction in fecal pellet output, respectively, in the first 15 min of exposure to a novel environment. The reduction remained significant in the older group for 2-h, and subsequent refeeding resulted also in a 60% and 69% reduction of defecation in the first hour, respectively. Thy1-aSyn mice (8-10 months) displayed increased α-synuclein in the myenteric plexuses with abundant varicose terminals surrounding pChAT-immunoreactive (ir) neurons, and only a few, nNOS-ir neurons. There were no conspicuous changes in pChAT- and nNOS-ir neurons, or TH- and VIP-ir nerve fibers. Thy1-aSyn mice aged 4-18 months had normal GE. CONCLUSIONS & INFERENCES: The occurrence of over-production of pre-synaptic α-synuclein in colonic myenteric ganglia several months before the loss of striatal dopamine may provide an anatomical basis for interference with cholinergic neuronal activation, causing an early impairment in defecation to stimuli.
Asunto(s)
Colon/fisiología , Defecación/fisiología , Ganglios Autónomos/metabolismo , Plexo Mientérico/metabolismo , alfa-Sinucleína/metabolismo , Animales , Colina O-Acetiltransferasa/metabolismo , Colon/inervación , Colon/fisiopatología , Ganglios Autónomos/fisiopatología , Vaciamiento Gástrico/fisiología , Masculino , Ratones , Ratones Transgénicos , Plexo Mientérico/fisiopatología , Neuronas/metabolismo , Óxido Nítrico Sintasa de Tipo I/metabolismo , Enfermedad de Parkinson/metabolismo , Enfermedad de Parkinson/fisiopatología , Tirosina 3-Monooxigenasa/metabolismoRESUMEN
Mitochondrial complex I inhibition has been implicated in the degeneration of midbrain dopaminergic (DA) neurons in Parkinson's disease. However, the mechanisms and pathways that determine the cellular fate of DA neurons downstream of the mitochondrial dysfunction have not been fully identified. We conducted cell-type specific gene array experiments with nigral DA neurons from rats treated with the complex I inhibitor, rotenone, at a dose that does not induce cell death. The genome wide screen identified transcriptional changes in multiple cell death related pathways that are indicative of a simultaneous activation of both degenerative and protective mechanisms. Quantitative PCR analyses of a subset of these genes in different neuronal populations of the basal ganglia revealed that some of the changes are specific for DA neurons, suggesting that these neurons are highly sensitive to rotenone. Our data provide insight into potentially defensive strategies of DA neurons against disease relevant insults.
Asunto(s)
Muerte Celular/genética , Dopamina/metabolismo , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Rotenona/farmacología , Sustancia Negra/efectos de los fármacos , Activación Transcripcional/efectos de los fármacos , Animales , Peso Corporal/efectos de los fármacos , Complejo I de Transporte de Electrón/antagonistas & inhibidores , Conducta Exploratoria/efectos de los fármacos , Expresión Génica , Perfilación de la Expresión Génica , Masculino , Mitocondrias/efectos de los fármacos , Análisis de Secuencia por Matrices de Oligonucleótidos , Reacción en Cadena de la Polimerasa , ARN Mensajero/metabolismo , Ratas , Rotenona/administración & dosificación , Sustancia Negra/metabolismo , Ácido gamma-Aminobutírico/metabolismoRESUMEN
Huntington's disease is a neurodegenerative disorder, caused by an elongation of CAG repeats in the huntingtin gene. Mice with an insertion of an expanded polyglutamine repeat in the mouse huntingtin gene (knock-in mice) most closely model the disease because the mutation is expressed in the proper genomic and protein context. However, few knock-in mouse lines have been extensively characterized and available data suggest marked differences in the extent and time course of their behavioral and pathological phenotype. We have previously described behavioral anomalies in the open field as early as 1 month of age, followed by the appearance at 2 months of progressive huntingtin neuropathology, in a mouse carrying a portion of human exon 1 with approximately 140 CAG repeats inserted into the mouse huntingtin gene. Here we extend these observations by showing that early behavioral anomalies exist in a wide range of motor (climbing, vertical pole, rotarod, and running wheel performance) and non-motor functions (fear conditioning and anxiety) starting at 1-4 months of age, and are followed by progressive gliosis and decrease in dopamine and cyclic AMP-regulated phosphoprotein with molecular weight 32 kDa (DARPP32) (12 months) and a loss of striatal neurons at 2 years. At this age, mice also present striking spontaneous behavioral deficits in their home cage. The data show that this line of knock-in mice reproduces canonical characteristics of Huntington's disease, preceded by deficits which may correspond to the protracted pre-manifest phase of the disease in humans. Accordingly, they provide a useful model to elucidate early mechanisms of pathophysiology and the progression to overt neurodegeneration.
Asunto(s)
Conducta Animal/fisiología , Enfermedad de Huntington/patología , Enfermedad de Huntington/psicología , Actividad Motora/fisiología , Neostriado/patología , Animales , Animales Recién Nacidos , Ansiedad/genética , Ansiedad/psicología , Condicionamiento Psicológico/fisiología , Emociones/fisiología , Miedo , Femenino , Técnicas de Sustitución del Gen , Suspensión Trasera/fisiología , Suspensión Trasera/psicología , Enfermedad de Huntington/genética , Procesamiento de Imagen Asistido por Computador , Inmunohistoquímica , Luz , Masculino , Ratones , Ratones Endogámicos C57BL , Enfermedades Neurodegenerativas/patología , Equilibrio Postural/fisiología , Desempeño Psicomotor/fisiologíaRESUMEN
Genetic variability in the alpha-synuclein gene and long-term exposure to the pesticide paraquat constitute possible risk factors for sporadic Parkinson's disease. The goal of the present study was to further characterize the effects of paraquat in mice as a model of Parkinson's disease and to determine whether it acted synergistically with alpha-synuclein over-expression to cause nigrostriatal cell death or dysfunction. Paraquat (10 mg/kg i.p.) was administered once a week for 3 weeks to mice over-expressing human alpha-synuclein under the Thy1 promoter and their wild-type littermates. The effect of paraquat on catecholaminergic neurons was reminiscent of that of Parkinson's disease, with preferential loss of dopaminergic neurons in the ventral tier of the substantia nigra pars compacta and loss of tyrosine hydroxylase staining in the locus coeruleus. alpha-Synuclein over-expression did not increase paraquat-induced cell loss, and paraquat did not worsen the behavioral deficits observed in the transgenic mice. However, paraquat markedly increased proteinase-K-resistant alpha-synuclein aggregates in substantia nigra of the transgenic mice. The data further validate the use of paraquat to model Parkinson's disease in mice and show that although paraquat and alpha-synuclein over-expression act synergistically to increase protein aggregation in vivo, this interaction does not result in short-term neuroprotection or increased vulnerability of nigrostriatal neurons.
Asunto(s)
Conducta Animal/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Síndromes de Neurotoxicidad , Paraquat , alfa-Sinucleína/metabolismo , Análisis de Varianza , Animales , Recuento de Células , Modelos Animales de Enfermedad , Humanos , Locus Coeruleus/efectos de los fármacos , Locus Coeruleus/patología , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Actividad Motora/efectos de los fármacos , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Síndromes de Neurotoxicidad/etiología , Síndromes de Neurotoxicidad/patología , Síndromes de Neurotoxicidad/fisiopatología , Desempeño Psicomotor/efectos de los fármacos , Sustancia Negra/efectos de los fármacos , Sustancia Negra/patología , Tirosina 3-Monooxigenasa/metabolismo , alfa-Sinucleína/genéticaRESUMEN
Overexpression of alpha-synuclein causes familial Parkinson's disease and abnormal aggregates of the protein are present in sporadic cases of the disease. We have examined the behavioral effects of direct and indirect dopaminergic agonists in transgenic mice expressing human alpha-synuclein under the Thy-1 promoter (Thy1-aSyn, alpha-synuclein overexpressor), which exhibit progressive impairments in behavioral tests sensitive to nigrostriatal dopamine dysfunction. Male Thy1-aSyn and wild-type mice received vehicle, benserazide/L-DOPA (25 mg/kg, i.p.), high (2 mg/kg, s.c.) and low doses (0.125, 0.25, 0.5 mg/kg, s.c.) of apomorphine, and amphetamine (5 mg/kg, i.p.), beginning at 3 months of age, and were tested on the challenging beam, spontaneous activity, pole test, and gait. l-DOPA had a paradoxical effect and worsened the deficits in Thy1-aSyn mice compared with controls, whereas the high dose of apomorphine only produced few deficits above those already present in Thy1-aSyn. In contrast to wild-type mice, Thy1-aSyn mice did not show amphetamine-induced stereotypies. The results indicate that chronic overexpression of alpha-synuclein led to abnormal pharmacological responses in mice.
Asunto(s)
Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Agonistas de Dopamina/efectos adversos , Predisposición Genética a la Enfermedad/genética , Enfermedad de Parkinson/metabolismo , alfa-Sinucleína/metabolismo , Anfetamina/efectos adversos , Animales , Apomorfina/efectos adversos , Conducta Animal/efectos de los fármacos , Conducta Animal/fisiología , Benserazida/efectos adversos , Encéfalo/fisiopatología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Discinesia Inducida por Medicamentos/genética , Discinesia Inducida por Medicamentos/metabolismo , Discinesia Inducida por Medicamentos/fisiopatología , Femenino , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Enfermedad de Parkinson/genética , Enfermedad de Parkinson/fisiopatología , Trastorno de Movimiento Estereotipado/genética , Trastorno de Movimiento Estereotipado/metabolismo , Trastorno de Movimiento Estereotipado/fisiopatología , alfa-Sinucleína/genéticaRESUMEN
Changes in cellular activity in the subthalamic nucleus are a cardinal feature of Parkinson's disease and occur in rodents after lesions of the nigrostriatal pathway, a model of Parkinson's disease. GABA-ergic neurons from the globus pallidus provide a major input to the subthalamic nucleus. Previous electrophysiological studies revealed temporal changes in the activity of pallidal neurons after nigrostriatal lesions in rats. However, little is known about the impact of these changes on GABAergic transmission in the subthalamic nucleus. We have examined the behavioral responses to a local administration of the GABA A agonist muscimol into the subthalamic nucleus. Muscimol (0.01 and 0.1 microg) induced orofacial dyskinesia in normal rats; this response was blunted 2 weeks but enhanced 2 months after a unilateral lesion of the nigrostriatal pathway. The early decrease in the behavioral response occurred at a time when increased expression of mRNA for glutamic acid decarboxylase, the enzyme of GABA synthesis, and burst firing have been reported in the globus pallidus, suggesting an adaptive post-synaptic response to increased GABAergic transmission in the subthalamic nucleus. In contrast, we now show that glutamic acid decarboxylase mRNA is unchanged in the globus pallidus at the later time point, when electrophysiological changes also subside in this region. The increased behavioral response at this later time point may reflect a decreased activity in GABAergic inputs to the subthalamic nucleus. The results show time-dependent changes in behavioral responses to GABA A receptor stimulation in the subthalamic nucleus which may reflect adaptive changes in postsynaptic inhibitory responses after dopaminergic lesions.
Asunto(s)
Conducta Animal/efectos de los fármacos , Cuerpo Estriado/fisiología , Agonistas del GABA/farmacología , Muscimol/farmacología , Sustancia Negra/fisiología , Núcleo Subtalámico/efectos de los fármacos , 2,3,4,5-Tetrahidro-7,8-dihidroxi-1-fenil-1H-3-benzazepina/farmacología , Análisis de Varianza , Animales , Autorradiografía/métodos , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/lesiones , Agonistas de Dopamina/farmacología , Relación Dosis-Respuesta a Droga , Hibridación in Situ/métodos , Masculino , Oxidopamina/farmacología , Ratas , Ratas Sprague-Dawley , Sustancia Negra/efectos de los fármacos , Sustancia Negra/lesiones , Núcleo Subtalámico/fisiología , Factores de Tiempo , Tritio/farmacologíaRESUMEN
The trinucleotide repeat disorders comprise an ever expanding list of diseases, all of which are caused by an unstable expanded trinucleotide repeat tract. Huntington's disease (HD) is a member of this family of diseases and more specifically, is a Type II trinucleotide repeat disorder. This means that the mutation in HD is an unstable expanded polyglutamine repeat tract, which is expressed at protein level. There is no cure or beneficial treatment for this fatal neurodegenerative disorder, and patients suffer from progressive motor, cognitive and psychiatric dysfunction. Recent years has seen the development of many genetic models of HD, which allow study of the early phases of disease process, at several different levels of cell function. In addition, these models are being used to investigate the potential of a variety of therapeutic agents for clinical use. Here we review these findings, and their implication for HD pathogenesis.
Asunto(s)
Modelos Animales de Enfermedad , Enfermedad de Huntington/genética , Proteínas del Tejido Nervioso/genética , Proteínas Nucleares/genética , Expansión de Repetición de Trinucleótido/genética , Animales , Humanos , Proteína Huntingtina , Enfermedad de Huntington/patología , Ratones , Ratones Noqueados , Ratones Transgénicos , Mutación , FenotipoRESUMEN
We examined passive and active membrane properties and synaptic responses of medium-sized spiny striatal neurons in brain slices from presymptomatic (approximately 40 days of age) and symptomatic (approximately 90 days of age) R6/2 transgenics, a mouse model of Huntington's disease (HD) and their age-matched wild-type (WT) controls. This transgenic expresses exon 1 of the human HD gene with approximately 150 CAG repeats and displays a progressive behavioral phenotype associated with numerous neuronal alterations. Intracellular recordings were obtained using standard techniques from R6/2 and age-matched WT mice. Few electrophysiological changes occurred in striatal neurons from presymptomatic R6/2 mice. The changes in this age group were increased neuronal input resistance and lower stimulus intensity to evoke action potentials (rheobase). Symptomatic R6/2 mice exhibited numerous electrophysiological alterations, including depolarized resting membrane potentials, increased input resistances, decreased membrane time constants, and alterations in action potentials. Increased stimulus intensities were required to evoke excitatory postsynaptic potentials (EPSPs) in neurons from symptomatic R6/2 transgenics. These EPSPs had slower rise times and did not decay back to baseline by 45 ms, suggesting a more prominent component mediated by activation of N-methyl-D-aspartate receptors. Neurons from both pre- and symptomatic R6/2 mice exhibited reduced paired-pulse facilitation. Data from biocytin-filled or Golgi-impregnated neurons demonstrated decreased dendritic spine densities, smaller diameters of dendritic shafts, and smaller dendritic fields in symptomatic R6/2 mice. Taken together, these findings indicate that passive and active membrane and synaptic properties of medium-sized spiny neurons are altered in the R6/2 transgenic. These physiological and morphological alterations will affect communication in the basal ganglia circuitry. Furthermore, they suggest areas to target for pharmacotherapies to alleviate and reduce the symptoms of HD.
Asunto(s)
Enfermedad de Huntington/patología , Enfermedad de Huntington/fisiopatología , Neostriado/patología , Neostriado/fisiopatología , Neuronas/patología , Neuronas/fisiología , Potenciales de Acción/fisiología , Animales , Estimulación Eléctrica , Electrofisiología , Potenciales Postsinápticos Excitadores/fisiología , Humanos , Técnicas In Vitro , Potenciales de la Membrana/fisiología , Ratones , Ratones Transgénicos , Neuronas/ultraestructura , Técnicas de Placa-Clamp , Fenotipo , Sinapsis/fisiologíaRESUMEN
Thermocoagulation of pial blood vessels overlying the cerebral cortex induces an ischemic degeneration of the cortex. We have previously shown with anatomical tracing techniques that thermocoagulatory lesions of the sensorimotor cortex trigger a robust axonal sprouting of contralateral cortical neurons into the denervated striatum. Similar sprouting was not observed after acute aspiration lesions of the same cortical region. We have now examined immunostaining for the growth-associated protein (GAP)-43 at the ultrastructural level after both types of lesions. A modest increase in growth cone-like structures was observed just below the corpus callosum after both lesions. However, GAP-43-positive growth cone-like structures were markedly increased in the denervated dorsolateral striatum only after thermocoagulatory lesions. In contrast, no significant increase in growth cone immunostaining was found in the dorsolateral striatum after aspiration lesions, confirming the absence of axonal sprouting in the dorsolateral striatum in this condition. Corticostriatal inputs make asymmetric synapses with dendritic spines of striatal neurons. As expected, the density of asymmetric synapses was markedly decreased in the dorsolateral striatum after aspiration lesions. However, it was not different from control after thermocoagulatory lesions that removed the same cortical area. The density of symmetric synapses was decreased after both types of lesions at 16 but not 42 days post-surgery. These data reveal that robust axonal and synaptic remodeling can occur in the dorsolateral striatum of adult rats after ischemic lesions of the cerebral cortex and further demonstrate marked differences in the degree of anatomical plasticity induced by two different types of cortical lesions.
Asunto(s)
Corteza Cerebral/lesiones , Electrocoagulación/efectos adversos , Conos de Crecimiento/ultraestructura , Neostriado/ultraestructura , Regeneración Nerviosa/fisiología , Plasticidad Neuronal/fisiología , Terminales Presinápticos/ultraestructura , Animales , Recuento de Células , Corteza Cerebral/metabolismo , Corteza Cerebral/ultraestructura , Cuerpo Calloso/lesiones , Cuerpo Calloso/metabolismo , Cuerpo Calloso/ultraestructura , Dendritas/metabolismo , Dendritas/ultraestructura , Desnervación/métodos , Proteína GAP-43/metabolismo , Conos de Crecimiento/metabolismo , Inmunohistoquímica , Masculino , Microscopía Electrónica , Neostriado/metabolismo , Terminales Presinápticos/metabolismo , Ratas , Ratas Sprague-DawleyRESUMEN
The endomorphins are recently discovered endogenous agonists for the mu-opioid receptor (Zadina et al., 1997). Endomorphins produce analgesia; however, their role in other brain functions has not been elucidated. We have investigated the behavioral effects of endomorphin-1 in the globus pallidus, a brain region that is rich in mu-opioid receptors and involved in motor control. Bilateral administration of endomorphin-1 in the globus pallidus of rats induced orofacial dyskinesia. This effect was dose-dependent and at the highest dose tested (18 pmol per side) was sustained during the 60 min of observation, indicating that endomorphin-1 does not induce rapid desensitization of this motor response. In agreement with a lack of desensitization of mu-opioid receptors, 3 hr of continuous exposure of the cloned mu receptor to endomorphin-1 did not diminish the subsequent ability of the agonist to inhibit adenylate cyclase activity in cells expressing the cloned mu-opioid receptor. Confirming the involvement of mu-opioid receptors, the behavioral effect of endomorphin-1 in the globus pallidus was blocked by the opioid antagonist naloxone and the mu-selective peptide antagonist Cys(2)-Tyr(3)-Orn(5)-Pen(7) amide (CTOP). Furthermore, the selective mu receptor agonist [d-Ala(2)-N-Me-Phe(4)-Glycol(5)]-enkephalin (DAMGO) also stimulated orofacial dyskinesia when infused into the globus pallidus, albeit transiently. Our findings suggest that endogenous mu agonists may play a role in hyperkinetic movement disorders by inducing sustained activation of pallidal opioid receptors.
Asunto(s)
Discinesia Inducida por Medicamentos/fisiopatología , Globo Pálido/efectos de los fármacos , Actividad Motora/efectos de los fármacos , Oligopéptidos/administración & dosificación , Receptores Opioides mu/efectos de los fármacos , Somatostatina/análogos & derivados , Animales , Conducta Animal/efectos de los fármacos , Catalepsia/inducido químicamente , Catalepsia/fisiopatología , Línea Celular , Colforsina/antagonistas & inhibidores , Colforsina/farmacología , AMP Cíclico/metabolismo , Relación Dosis-Respuesta a Droga , Vías de Administración de Medicamentos , Discinesia Inducida por Medicamentos/etiología , Discinesia Inducida por Medicamentos/prevención & control , Encefalina Ala(2)-MeFe(4)-Gli(5)/farmacología , Globo Pálido/fisiopatología , Humanos , Masculino , Ratones , Naloxona/farmacología , Antagonistas de Narcóticos/farmacología , Oligopéptidos/antagonistas & inhibidores , Oligopéptidos/metabolismo , Unión Proteica/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Receptores Opioides delta/genética , Receptores Opioides delta/metabolismo , Receptores Opioides kappa/genética , Receptores Opioides kappa/metabolismo , Receptores Opioides mu/genética , Receptores Opioides mu/metabolismo , Somatostatina/farmacología , TransfecciónRESUMEN
Proteolysis of mutant huntingtin (htt) has been hypothesized to occur in Huntington's disease (HD) brains. Therefore, this in vivo study examined htt fragments in cortex and striatum of adult HD and control human brains by Western blots, using domain-specific anti-htt antibodies that recognize N- and C-terminal domains of htt (residues 181-810 and 2146-2541, respectively), as well as the 17 residues at the N terminus of htt. On the basis of the patterns of htt fragments observed, different "protease-susceptible domains" were identified for proteolysis of htt in cortex compared with striatum, suggesting that htt undergoes tissue-specific proteolysis. In cortex, htt proteolysis occurs within two different N-terminal domains, termed protease-susceptible domains "A" and "B." However, in striatum, a different pattern of fragments indicated that proteolysis of striatal htt occurred within a C-terminal domain termed "C," as well as within the N-terminal domain region designated "A". Importantly, striatum from HD brains showed elevated levels of 40-50 kDa N-terminal and 30-50 kDa C-terminal fragments compared with that of controls. Increased levels of these htt fragments may occur from a combination of enhanced production or retarded degradation of fragments. Results also demonstrated tissue-specific ubiquitination of certain htt N-terminal fragments in striatum compared with cortex. Moreover, expansions of the triplet-repeat domain of the IT15 gene encoding htt was confirmed for the HD tissue samples studied. Thus, regulated tissue-specific proteolysis and ubiquitination of htt occur in human HD brains. These results suggest that the role of huntingtin proteolysis should be explored in the pathogenic mechanisms of HD.
Asunto(s)
Encéfalo/metabolismo , Enfermedad de Huntington/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Proteínas Nucleares/metabolismo , Fragmentos de Péptidos/metabolismo , Péptido Hidrolasas/metabolismo , Anciano , Especificidad de Anticuerpos , Western Blotting , Encéfalo/patología , Corteza Cerebral/metabolismo , Corteza Cerebral/patología , Cuerpo Estriado/metabolismo , Cuerpo Estriado/patología , Humanos , Proteína Huntingtina , Enfermedad de Huntington/genética , Enfermedad de Huntington/patología , Persona de Mediana Edad , Proteínas del Tejido Nervioso/genética , Proteínas Nucleares/genética , Especificidad de Órganos , Reacción en Cadena de la Polimerasa , Estructura Terciaria de Proteína , Putamen/metabolismo , Putamen/patología , Expansión de Repetición de Trinucleótido , Ubiquitinas/metabolismoRESUMEN
Peripheral administration of the 5-hydroxytryptamine (5-HT)(2C/1B) agonist 1-(m-chlorophenyl)piperazine (m-CPP) produces abnormal orofacial movements in rats. We have previously shown that this behavior is mediated by 5-HT(2C) receptors in the subthalamic nucleus [Neuroscience 72 (1996) 117]. The present studies examined this effect after serotonin depletion to determine whether removal of endogenous serotonin affected this behavioral response and/or subthalamic 5-HT(2C) receptors. Rats received an intraventricular infusion of the neurotoxin 5,7-dihydroxytryptamine (5,7-DHT, 100 mg/10 ml) or vehicle after desipramine pretreatment (25 mg/kg ip). The efficacy of serotonin depletion was confirmed by a decrease in serotonin uptake sites measured by autoradiography. Oral dyskinesia induced by peripheral administration of m-CPP (1.0 mg/kg ip) was markedly increased in lesioned rats compared to sham-operated controls 4 and 8 but not 12 days after the lesion. A subset of lesioned rats that displayed transient seizures after m-CPP injection did not prevent the measurement of oral dyskinesia during the observation period. No differences in 5-HT(2C) receptor levels were found with ligand-binding autoradiography in the subthalamic nucleus, or in other brain regions that express this receptor, in rats sacrificed 5 days following 5,7-DHT lesions. The data indicate that lesion of serotonergic neurons in adult rats induces a transient increase in motor responses mediated by subthalamic 5-HT(2C) receptors. These data suggest that functional alterations in serotonergic transmission in the subthalamic nucleus may be involved in the pathophysiology of hyperkinetic movement disorders.
Asunto(s)
Discinesia Inducida por Medicamentos/metabolismo , Piperazinas , Receptores de Serotonina/metabolismo , Agonistas de Receptores de Serotonina , Núcleo Subtalámico/metabolismo , 5,7-Dihidroxitriptamina , Animales , Conducta Animal/efectos de los fármacos , Conducta Animal/fisiología , Masculino , Piperazinas/farmacología , Ratas , Ratas Sprague-Dawley , Receptor de Serotonina 5-HT2C , Serotoninérgicos , Agonistas de Receptores de Serotonina/farmacología , Núcleo Subtalámico/lesionesRESUMEN
The technique of in situ nick translation (ISNT) is used to detect DNA strand breaks in tissue sections at the cellular level with great sensitivity. In fact, ISNT can be used to detect DNA damage in a single cell, which is particularly useful to assess programmed cell death during development. One crucial advantage of ISNT is the anatomical resolution that permits a detailed topographical analysis of DNA damage. This can be useful to identify cells that are more vulnerable to an experimental insult. Furthermore, cells with DNA damage can be identified morphologically with this method. This can be of interest to determine whether cells that exhibit DNA damage already exhibit clear features of dying cells or are still relatively intact morphologically. This can be useful to identify the mode of cell death involved. This unit provides a protocol that describes tissue preparation, in situ nick translation and emulsion autoradiography.
Asunto(s)
Daño del ADN/genética , Etiquetado Corte-Fin in Situ/métodos , Tejido Nervioso/fisiología , Animales , Roturas del ADN de Cadena Simple , Humanos , Tejido Nervioso/químicaRESUMEN
Local infusions of the nonselective dopaminergic agonist apomorphine into the subthalamic nucleus of rats has been shown to elicit orofacial dyskinesia which can be blocked by D1 but not D2 receptor antagonists. In the present study, we show that the selective D1 agonist A77636 also induces orofacial dyskinesia when injected into the subthalamic nucleus of awake rats, thus confirming a role for D1 receptors in this effect. We also examined the dyskinesia induced by intrasubthalamic injections of apomorphine in rats with an ipsilateral lesion of the nigrostriatal pathway. The orofacial response to local administration of apomorphine (1.0 microg) into the subthalamic nucleus was markedly increased in the lesioned rats. As in control rats, the enhanced behavioral response seen in lesioned rats was blocked by peripheral administration of D1 antagonists. Although D1 receptor binding autoradiography revealed no difference in D1 receptor binding in the subthalamic nucleus on the side of the lesion compared to controls, D1 binding was higher in the subthalamic nucleus on the side of the lesion compared to the contralateral side. The increased behavioral response observed after unilateral dopamine denervation suggests that the subthalamic nucleus is tonically regulated by dopaminergic projections from the substantia nigra. Furthermore, the data suggest that subthalamic D1 receptors may be involved in the development of dyskinesia induced by dopaminergic drugs.
Asunto(s)
Conducta Animal/efectos de los fármacos , Cuerpo Estriado/fisiopatología , Dopamina/fisiología , Sustancia Negra/fisiopatología , Núcleo Subtalámico/fisiología , Adamantano/análogos & derivados , Adamantano/farmacología , Animales , Apomorfina/farmacología , Autorradiografía , Benzazepinas/farmacología , Benzopiranos/farmacología , Cuerpo Estriado/patología , Desnervación , Agonistas de Dopamina/farmacología , Antagonistas de Dopamina/farmacología , Masculino , Oxidopamina , Ratas , Ratas Sprague-Dawley , Receptores de Dopamina D1/análisis , Receptores de Dopamina D1/fisiología , Sustancia Negra/patología , Núcleo Subtalámico/química , SimpaticolíticosRESUMEN
The loss of dopaminergic innervation of the basal ganglia, a group of subcortical regions involved in motor control, is the hallmark of Parkinson's disease. The resulting molecular and cellular alterations mediate behavioral deficits and may modify neuronal responses to other neurotransmitters. In the present study, we sought to determine the effects of chronic dopamine (DA) depletion on responses mediated by stimulation of serotonergic 2C (5-HT(2C)) receptors, a serotonergic receptor subtype present in discrete regions of the basal ganglia. Specifically, the effects of unilateral lesions of nigrostriatal DA neurons on oral dyskinesia and Fos protein expression induced by the non-selective 5-HT(2C) agonist 1-(m-chlorophenyl)piperazine (m-CPP) were examined. Confirming previous findings, both peripheral and local injections of m-CPP into the subthalamic nucleus elicited oral dyskinesia. Nigrostriatal lesions markedly enhanced oral bouts induced by peripheral but not intrasubthalamic administration of m-CPP. In intact rats, Fos expression was increased by m-CPP (1 mg/kg, i.p.) in the striatum and the subthalamic nucleus. After nigrostriatal lesions, m-CPP-induced Fos expression remained unchanged in the subthalamic nucleus but was reduced in the medial quadrants of the striatum and was markedly enhanced in the entopeduncular nucleus. These data demonstrate regionally specific alterations in behavioral and cellular responses to a serotonergic agonist in an animal model of Parkinson's disease.
Asunto(s)
Cuerpo Estriado/fisiología , Discinesia Inducida por Medicamentos/fisiopatología , Regulación de la Expresión Génica/fisiología , Genes fos , Neuronas/fisiología , Piperazinas/farmacología , Agonistas de Receptores de Serotonina/farmacología , Sustancia Negra/fisiología , Animales , Cuerpo Estriado/efectos de los fármacos , Dopamina/fisiología , Regulación de la Expresión Génica/efectos de los fármacos , Masculino , Actividad Motora/efectos de los fármacos , Neuronas/efectos de los fármacos , Oxidopamina , Proteínas Proto-Oncogénicas c-fos/genética , Ratas , Ratas Sprague-Dawley , Receptor de Serotonina 5-HT2C , Receptores de Serotonina/fisiología , Sustancia Negra/efectos de los fármacos , Núcleos Talámicos/efectos de los fármacos , Núcleos Talámicos/patología , Núcleos Talámicos/fisiología , Tirosina 3-Monooxigenasa/metabolismoRESUMEN
Huntington's disease is a devastating progressive neurodegenerative illness characterized by massive neuronal loss in the striatum. It is caused by the presence of an expanded CAG repeat in the gene encoding huntingtin, a protein of unknown function. We have examined the expression of neurotransmitters and other antigens present in striatal neurons with immunohistochemistry, and the level of expression of mRNAs encoding enkephalin, substance P, and glutamic acid decarboxylases with quantitative in situ hybridization histochemistry, in the striatum of two mouse models of Huntington's disease: transgenic animals expressing exon 1 of the human huntingtin gene with 144 CAG repeats and "knock-in" mice containing a chimeric mouse/human exon 1 with 71 or 94 CAG repeats inserted by homologous targeting. Although the transgenic (but not the knock-in) mice were previously shown to display prominent huntingtin- and ubiquitin-containing nuclear inclusions in striatal neurons, in situ nick translation followed by emulsion autoradiography did not reveal any DNA damage in striatum or cortex in these mice. Immunolabeling for calbindin D 28K, enkephalin, substance P, glutamic acid decarboxylases (M(r) 65,000 or 67,000, GAD65 and GAD67), somatostatin, choline acetyltransferase, parvalbumin, and glial fibrillary acidic protein were remarkably similar in transgenic, knock-in, and wild-type mice. Both transgenic and knock-in mice, however, showed a marked decrease in the level of expression of enkephalin mRNA in striatal neurons without significant decreases in mRNAs encoding substance P, GAD65, or GAD67. The data indicate that decreased expression of enkephalin mRNA may be an early sign of neuronal dysfunction due to the Huntington's disease mutation.